JP2011168588A5 - - Google Patents

Download PDF

Info

Publication number
JP2011168588A5
JP2011168588A5 JP2011026980A JP2011026980A JP2011168588A5 JP 2011168588 A5 JP2011168588 A5 JP 2011168588A5 JP 2011026980 A JP2011026980 A JP 2011026980A JP 2011026980 A JP2011026980 A JP 2011026980A JP 2011168588 A5 JP2011168588 A5 JP 2011168588A5
Authority
JP
Japan
Prior art keywords
gene
compound
apoptosis inducer
test compound
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011026980A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011168588A (ja
JP5213972B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2011026980A priority Critical patent/JP5213972B2/ja
Priority claimed from JP2011026980A external-priority patent/JP5213972B2/ja
Publication of JP2011168588A publication Critical patent/JP2011168588A/ja
Publication of JP2011168588A5 publication Critical patent/JP2011168588A5/ja
Application granted granted Critical
Publication of JP5213972B2 publication Critical patent/JP5213972B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2011026980A 2004-04-09 2011-02-10 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤 Expired - Fee Related JP5213972B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2011026980A JP5213972B2 (ja) 2004-04-09 2011-02-10 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004115404 2004-04-09
JP2004115404 2004-04-09
JP2011026980A JP5213972B2 (ja) 2004-04-09 2011-02-10 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006512126A Division JP4761389B2 (ja) 2004-04-09 2005-04-08 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012046652A Division JP5390653B2 (ja) 2004-04-09 2012-03-02 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Publications (3)

Publication Number Publication Date
JP2011168588A JP2011168588A (ja) 2011-09-01
JP2011168588A5 true JP2011168588A5 (enExample) 2012-04-19
JP5213972B2 JP5213972B2 (ja) 2013-06-19

Family

ID=35124844

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006512126A Expired - Fee Related JP4761389B2 (ja) 2004-04-09 2005-04-08 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤
JP2011026980A Expired - Fee Related JP5213972B2 (ja) 2004-04-09 2011-02-10 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤
JP2012046652A Expired - Fee Related JP5390653B2 (ja) 2004-04-09 2012-03-02 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006512126A Expired - Fee Related JP4761389B2 (ja) 2004-04-09 2005-04-08 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012046652A Expired - Fee Related JP5390653B2 (ja) 2004-04-09 2012-03-02 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Country Status (5)

Country Link
US (3) US8193332B2 (enExample)
EP (4) EP2495324B1 (enExample)
JP (3) JP4761389B2 (enExample)
KR (1) KR101234281B1 (enExample)
WO (1) WO2005097189A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4299299B2 (ja) 2003-05-19 2009-07-22 株式会社ジーンケア研究所 癌細胞に対するアポトーシス誘導剤
EP2495324B1 (en) 2004-04-09 2015-03-04 Genecare Research Institute Co., Ltd Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
WO2006054625A1 (ja) * 2004-11-19 2006-05-26 Genecare Research Institute Co., Ltd. 癌細胞特異的細胞増殖抑制剤
WO2006084694A2 (en) * 2005-02-10 2006-08-17 Centre National De La Recherche Scientifique Use of the mcm8 gene for the preparation of a pharmaceutical composition
WO2007013480A2 (en) * 2005-07-29 2007-02-01 Oncotherapy Science, Inc. Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
GB0606096D0 (en) * 2006-03-27 2006-05-03 Cbmm Sa Screening method
JPWO2008047574A1 (ja) * 2006-09-28 2010-02-25 株式会社ジーンケア研究所 抗癌剤増感剤
JP4940412B2 (ja) * 2006-10-16 2012-05-30 財団法人ヒューマンサイエンス振興財団 抗癌性物質のスクリーニング方法
WO2008048120A2 (en) * 2006-10-17 2008-04-24 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders
TWI494319B (zh) * 2007-02-21 2015-08-01 Oncotherapy Science Inc 表現腫瘤相關抗原之癌症的胜肽疫苗
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
WO2010034487A2 (en) * 2008-09-23 2010-04-01 Silence Therapeutics Ag Means for inhibiting the expression of orc-1
WO2010045526A1 (en) * 2008-10-17 2010-04-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Geminin inhibitors as tumor treatment
JP6099868B2 (ja) * 2008-12-04 2017-03-22 クルナ・インコーポレーテッド サーチュイン１（ｓｉｒｔ１）に対する天然アンチセンス転写物の抑制によるサーチュイン１関連疾患の治療
EP2963116B1 (en) * 2009-03-04 2020-11-11 CuRNA, Inc. Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1
US8435961B2 (en) * 2009-06-26 2013-05-07 Massachusetts Institute Of Technology Methods and compositions for increasing the activity of inhibitory RNA
US8268550B2 (en) * 2009-06-26 2012-09-18 Massachusetts Institute Of Technology Compositions and methods for identification of PARP function, inhibitors, and activators
WO2010151664A2 (en) 2009-06-26 2010-12-29 Massachusetts Institute Of Technology Compositions and methods for treating cancer and modulating stress granule formation
EP2985348B1 (en) * 2009-07-24 2020-12-30 CuRNA, Inc. Treatment of sirtuin 6 (sirt6) related diseases by inhibition of natural antisense transcript to sirt6
EP3533797B1 (en) 2010-02-17 2023-12-20 Takeda Pharmaceutical Company Limited Heterocyclic compound
US20130071395A1 (en) * 2010-05-28 2013-03-21 Case Western Reserve University Compositions and methods for treating pathologies
WO2012090479A1 (en) * 2010-12-28 2012-07-05 Oncotherapy Science, Inc. Mcm7 as a target gene for cancer therapy and diagnosis
WO2013142817A2 (en) 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
ES2872967T3 (es) * 2012-06-29 2021-11-03 Celgene Corp Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
US9512486B2 (en) * 2012-08-06 2016-12-06 The Institute Of Cancer Research: Royal Cancer Hospital Materials, methods, and systems for treating cancer
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
KR101623814B1 (ko) 2014-02-21 2016-05-24 두산중공업 주식회사 수냉각 발전기의 분리형 냉각수 순환 구조 및 그에 따른 냉각 방법
JP2015167527A (ja) * 2014-03-07 2015-09-28 学校法人東京理科大学 標的タンパク質の量の低減のためのポリペプチド、単離された核酸、組み換えベクター、及び形質転換体
WO2016102517A1 (en) * 2014-12-23 2016-06-30 Centre National De La Recherche Scientifique Use of rad18 inhibitors in the treatment of tumors
CN104673801B (zh) * 2015-02-12 2018-09-11 中山大学附属第三医院 一种肝癌基因ndc80及其应用
EP4060344A1 (en) 2015-06-08 2022-09-21 Arquer Diagnostics Limited Methods and kits
EP3304082B1 (en) 2015-06-08 2020-05-13 Arquer Diagnostics Limited Methods for analysing a urine sample
AU2017327384B2 (en) 2016-09-13 2021-05-20 The Jackson Laboratory Targeted enhanced DNA demethylation
WO2018079287A1 (ja) * 2016-10-26 2018-05-03 デンカ株式会社 変異型ヒトＤＮＡポリメラーゼε
US20200121703A1 (en) * 2017-06-26 2020-04-23 The Cleveland Clinic Foundation Cancer treatment
EP3851528A4 (en) * 2018-09-12 2023-12-06 Institute for Basic Science COMPOSITION FOR INDUCATING DEATH OF CELLS HAVING MUTATED GENE AND METHOD FOR INDUCATING DEATH OF CELLS HAVING MODIFIED GENE USING THE COMPOSITION
JP2022020872A (ja) * 2020-06-01 2022-02-02 均 石井 抗がん剤。

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919643A (en) 1996-06-11 1999-07-06 Advanced Research & Technology Institute Methods and compositions for the use of apurinic/apyrimidinic endonucleases
GB0004193D0 (en) * 2000-02-22 2000-04-12 Isis Innovation A genetic determinant for malignant melanoma
WO2002009573A2 (en) * 2000-07-31 2002-02-07 The Brigham And Women's Hospital, Inc. Prognostic classification of endometrial cancer
CN100523215C (zh) 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
US7892730B2 (en) * 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
WO2002102981A2 (en) * 2001-06-15 2002-12-27 The Trustees Of Columbia University In The City Of New York SIR2α-BASED THERAPEUTIC AND PROPHYLACTIC METHODS
AU2002362030A1 (en) 2001-11-27 2003-06-10 Fred Hutchinson Cancer Research Center Methods for inhibiting deacetylase activity
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
EP1519736A2 (en) * 2002-06-12 2005-04-06 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Use of hec1 antagonists in the treatment of proliferative disorders and cancer
AU2003299378A1 (en) * 2002-10-11 2004-05-04 Board Of Regents, The University Of Texas System Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
EP2305813A3 (en) * 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
CA2522299A1 (en) * 2003-04-15 2004-10-28 Avalon Pharmaceuticals, Inc Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
AU2003224132A1 (en) * 2003-04-24 2004-11-19 Galapagos Genomics N.V. Effective sirna knock-down constructs
JP4299299B2 (ja) 2003-05-19 2009-07-22 株式会社ジーンケア研究所 癌細胞に対するアポトーシス誘導剤
EP2495324B1 (en) 2004-04-09 2015-03-04 Genecare Research Institute Co., Ltd Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
WO2006054625A1 (ja) 2004-11-19 2006-05-26 Genecare Research Institute Co., Ltd. 癌細胞特異的細胞増殖抑制剤

Similar Documents

Publication Publication Date Title
JP2011037847A5 (enExample)
Li et al. Long non‐coding RNA FOXP 4‐AS 1 is an unfavourable prognostic factor and regulates proliferation and apoptosis in colorectal cancer
Schmitt et al. Long noncoding RNAs in cancer pathways
Yu et al. Downregulation of miR‐29 contributes to cisplatin resistance of ovarian cancer cells
Shibata et al. The flavonoid apigenin inhibits hepatitis C virus replication by decreasing mature microRNA122 levels
Neudecker et al. Emerging roles for microRNAs in perioperative medicine
Alegre et al. Circulating biomarkers in malignant melanoma
Nidadavolu et al. Identification of microRNAs dysregulated in cellular senescence driven by endogenous genotoxic stress
Wang et al. microRNA-200c modulates the epithelial-to-mesenchymal transition in human renal cell carcinoma metastasis
Kong et al. Upregulated microRNA-29a by hepatitis B virus X protein enhances hepatoma cell migration by targeting PTEN in cell culture model
Xue et al. MicroRNA-targeted therapeutics for lung cancer treatment
Wang et al. miR-197: A novel biomarker for cancers
Yang et al. The emerging roles of circular RNAs in ovarian cancer
Wang et al. Upregulation of microRNA-524-5p enhances the cisplatin sensitivity of gastric cancer cells by modulating proliferation and metastasis via targeting SOX9
JP2011162558A5 (enExample)
HK1200837A1 (en) Compositions and methods for silencing aldehyde dehydrogenase
WO2014022826A3 (en) Biomarker associated with risk of melanoma reoccurrence
EP2596136A4 (en) PLASMA MICRO RNA MARKER AND NEW METHOD FOR DIAGNOSIS OF HEPATOCELLULAR CARCINOMA
NZ617003A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
NO20092965L (no) Sammensetninger og fremgangsmater for a forhindre kreft med cupredoksiner
Deng et al. MiR-506 suppresses cell proliferation and tumor growth by targeting Rho-associated protein kinase 1 in hepatocellular carcinoma
WO2012102527A3 (ko) 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도
BR112013002738A2 (pt) métodos e compostos para o diagnóstico e o tratamento do câncer
JP2014221834A5 (enExample)
JP2016506412A5 (enExample)